Jushi Holdings Inc. (JUSH.CN) Investment Analysis

1. Executive Summary

Jushi Holdings Inc. ("Jushi" or the "Company") operates as a vertically integrated, multi-state cannabis operator (MSO) in the United States, focusing its strategic efforts on building a dense operational footprint in high-barrier, limited-license markets. Headquartered in Boca Raton, Florida, the Company manages a portfolio of cultivation, processing, retail, and distribution assets, primarily concentrated in Pennsylvania, Virginia, and Ohio, with additional operations in Massachusetts, Illinois, Nevada, and California. As of the third quarter of 2025, Jushi’s retail network comprises 41 operating dispensaries under the "Beyond Hello™" banner, supported by a suite of proprietary consumer brands including The Bank, The Lab, Seche, Tasteology, and Hijinks.

The investment narrative for Jushi is defined by a distinct "distressed asset to turnaround" trajectory. Unlike Tier 1 MSOs that pursued aggressive nationwide scale funded by equity, Jushi historically targeted distressed assets and license applications in jurisdictions with favorable supply-demand dynamics. This strategy has resulted in a concentrated portfolio that is highly levered to specific state-level regulatory catalysts—most notably the potential transition to adult-use sales in Pennsylvania and the activation of a commercial adult-use market in Virginia.

Financially, Jushi is navigating a critical stabilization phase. For the third quarter of 2025, the Company reported revenue of $65.7 million and an Adjusted EBITDA of $12.8 million, translating to a margin of 19.5%. While operational discipline has improved gross margins to 46.7%, the Company remains burdened by a heavy debt load and significant interest expenses, resulting in a net loss of $23.7 million for the quarter. The Company faces a "debt wall" in December 2026, creating a binary risk profile: if Jushi can bridge its liquidity needs to realize the benefits of federal rescheduling and state-level reform, the equity offers substantial upside through deleveraging and multiple expansion. Conversely, failure to manage upcoming maturities or regulatory delays could necessitate dilutive restructuring.

2. Business Drivers & Strategic Overview

Jushi’s business model is predicated on maximizing vertical integration in states where license caps restrict competition. The Company’s strategic roadmap, termed the "7 and 7" expansion plan, aims to densify its retail network to absorb expanded cultivation capacity.

Core Revenue Drivers

1. Retail-First Expansion (Beyond Hello™ & Nature's Remedy): Retail operations constitute the primary revenue engine for Jushi. The Company’s "retail-first" philosophy is designed to secure shelf space for its own brands, thereby capturing the full vertical margin.

• Footprint Evolution: As of late 2025, Jushi operates 41 dispensaries. The growth in store count has been targeted rather than scattershot. For instance, the recent opening of the Parma, Ohio location (operating under a management services agreement pending transfer) capitalizes on Ohio’s transition to adult-use sales.

• Ohio Expansion: Ohio represents a distinct near-term revenue driver. Following the launch of adult-use sales, Jushi has aggressively expanded to its statutory cap of stores. Retail revenue in Ohio increased by $3.9 million in Q3 2025 compared to the prior year, driven by the addition of five new dispensaries and the conversion of medical traffic to adult-use volumes.

• New Jersey Entry: The Company is in the process of entering the lucrative New Jersey market with planned openings in Little Ferry (expected late 2025) and Mount Laurel (1H 2026). This entry is strategic, placing stores in high-density areas to capture cross-border traffic and local demand in a market that has already surpassed $1 billion in annual sales.

2. Vertical Integration & Private Label Penetration: A critical metric for Jushi’s profitability is the "vertical sell-through rate"—the percentage of retail revenue derived from Jushi’s own manufactured products.

• Margin Defense: In Q3 2025, Jushi-branded products accounted for 56% of total retail revenue, a 110 basis point increase year-over-year. By controlling the supply chain from seed to sale, Jushi mitigates the impact of wholesale price compression, a pervasive trend in maturing markets like Massachusetts and Pennsylvania.

• Brand Portfolio Stratification: Jushi has segmented its product offerings to address various consumer price points.

  • The Bank and Flower Foundry target the premium flower consumer.

  • Seche serves the value/volume segment, crucial for moving biomass in price-compressed markets.

  • The Lab and Tasteology cover concentrates and edibles.

  • Hijinks and Shayo (a partnership with Bravo TV personality Stacey Rusch) target lifestyle and demographic-specific niches. The introduction of 821 new SKUs in Q3 2025 alone demonstrates a rapid innovation cycle designed to keep pace with changing consumer preferences.

3. Wholesale Operations: While secondary to retail, wholesale revenue serves as a vital release valve for cultivation assets. Wholesale revenue grew 23% sequentially in Q3 2025, driven by improved yields and potency at the Company’s grower-processor facilities. This segment is particularly important in Virginia, where Jushi holds a monopoly-style permit for a specific Health Service Area (HSA), allowing it to supply other operators who may lack cultivation capacity.

Strategic Growth Initiatives

Operational Efficiency & Automation: To combat the "race to the bottom" in cannabis pricing, Jushi has invested heavily in facility upgrades. In Pennsylvania and Virginia, the Company has implemented automation in cultivation and processing. Management has noted a 13% year-over-year increase in yields, attributed to better genetics and facility management. These efficiency gains are directly responsible for the gross margin expansion to 46.7% in Q3 2025, despite lower average selling prices per unit.

The "Three-State" Call Option: Jushi’s strategic value is heavily concentrated in three jurisdictions:

• Pennsylvania (PA): Jushi is one of the dominant players in PA with 18 dispensaries. The market is currently medical-only but generates over $1.2 billion annually. The "prize" is adult-use legalization, which is actively championed by Governor Shapiro to generate an estimated $250 million+ in annual tax revenue. Jushi’s existing infrastructure is built to support a market that could double in size overnight upon legislative approval.

• Virginia (VA): Jushi operates exclusively in HSA II (Northern Virginia), a wealthy and densely populated region. While adult-use possession is legal, commercial sales have been delayed. The "Joint Commission on the Future of Cannabis Sales" has proposed a framework for sales to begin in November 2026. Jushi’s vertically integrated permit creates a formidable moat in this region.

• Ohio (OH): With the recent activation of adult-use sales, Ohio is the current growth engine. Jushi’s strategy here is execution-focused: maximizing throughput in its five operational stores and bringing the remaining licensed locations online rapidly.

Competitive Advantages

• Limited-License Moat: Jushi operates primarily in states that limit the number of licenses (PA, VA, OH). This contrasts with competitors in unlimited license states (like Michigan or Oregon) who face hyper-competition. In Virginia, the HSA model effectively grants a regional oligopoly.

• Insider Alignment: CEO Jim Cacioppo holds a significant equity stake (~20% including warrants), aligning management incentives with shareholder value preservation. This ownership structure discourages reckless dilution and encourages a focus on cash flow over "growth at all costs."

3. Financial Performance & Valuation

Historical Performance (2024–2025)

Jushi’s financial performance over the last 24 months reflects a company transitioning from aggressive build-out to operational optimization. The focus has shifted from topline growth to margin preservation and cash flow generation.

Key Financial Metrics Trend (Quarterly):

Analysis of Trends:

• Revenue Stability: Revenue has remained relatively flat to slightly up ($61.6M to $65.7M YoY). The lack of explosive growth is attributed to price compression in wholesale markets (MA, IL) offsetting volume gains in retail (OH, VA). The Ohio adult-use launch is the primary driver of the recent sequential uptick.

• Margin Recovery: Gross margins bottomed in Q4 2024 at 38.6% and have since rebounded to 46.7% in Q3 2025. This 800+ basis point recovery validates management's claims regarding efficiency improvements and the benefits of increased vertical sell-through.

• Net Loss Persistence: Despite solid EBITDA, Jushi consistently posts net losses ($23.7M in Q3 2025). This is driven by non-operating costs:

  • Interest Expense: Approximately $10.3 million per quarter.

  • Taxation: The punitive impact of Section 280E prevents the deduction of standard operating expenses, keeping the effective tax rate abnormally high.

  • Derivative Liabilities: Fair value adjustments on warrants and debt instruments contribute to volatility in the bottom line ($6.3M loss in Q3 2025).

Liquidity Position: As of September 30, 2025, Jushi held $26.2 million in cash, cash equivalents, and restricted cash. While the company generated $6.1 million in operating cash flow in the quarter, capital expenditures (CapEx) for new store openings and facility upgrades continue to consume cash. The liquidity runway remains tight relative to the debt load.

Current Valuation Multiples

Jushi currently trades at a valuation that reflects "distressed" status compared to its Tier 1 peers. The market is pricing in the risk of the 2026 debt maturity and the uncertainty of regulatory timing.

Market Data (as of Jan 3, 2026):

• Share Price: ~$0.85 CAD / ~$0.60 USD.

• Shares Outstanding: ~196.7 million (Basic) / ~300 million (Fully Diluted).

• Market Cap: ~$118 million USD (Basic).

• Total Debt: ~$225 million USD (Principal).

• Cash: ~$26 million USD.

• Enterprise Value (EV): ~$317 million USD.

Valuation Multiples (2025 Estimates):

• Revenue Run-Rate: ~$263 million ($65.7M x 4).

• EBITDA Run-Rate: ~$51 million ($12.8M x 4).

• EV / Revenue: 1.2x

• EV / EBITDA: 6.2x

Peer Comparison:

• Tier 1 MSOs (Green Thumb, Trulieve): Typically trade at 8.0x – 10.0x EV/EBITDA and 2.0x – 3.0x EV/Revenue.

• Tier 2 MSOs (Verano, Cresco): Trade in the 5.0x – 7.0x range.

• Observation: Jushi trades at the lower end of the Tier 2 range. This discount is a direct reflection of its higher leverage ratio (Debt/EBITDA > 4.0x) compared to leaders like Green Thumb (Debt/EBITDA < 2.0x).

4. Risk Assessment & Macroeconomic Considerations

The "Debt Wall" (Solvency Risk)

The single most significant risk factor for Jushi is its capital structure. The Company carries a substantial debt load with concentrated maturities.

• December 2026 Cliff: The Company has approximately $75.5 million in Second Lien Notes maturing in December 2026. Additionally, the $48.5 million Term Loan (refinanced via SunStream) has a maturity date tied to the Second Lien Notes (maturing 91 days prior if the notes are not refinanced). This creates a "cross-default" style dynamic where failure to address the 2026 notes triggers a cascade of maturities.

• Cost of Capital: The recent SunStream refinancing carries an interest rate of 12.25%. This high cost of capital consumes a vast portion of operating income, suppressing free cash flow generation. In a "higher-for-longer" rate environment, refinancing the 2026 notes could prove prohibitively expensive or require equity sweeteners (warrants), leading to dilution.

Regulatory Stasis & Political Risk

• Federal Rescheduling Delays: The anticipated move of cannabis to Schedule III (which would eliminate Section 280E taxes) is currently bogged down in administrative procedures. The DEA hearing scheduled for January 2025 was postponed. While Executive Orders push for expedition, the timeline remains uncertain. A delay beyond 2026 would be catastrophic for Jushi's cash flow planning, which likely assumes tax relief.

• State-Level Delays (PA & VA):

  • Pennsylvania: While Governor Shapiro supports legalization, the Republican-controlled Senate has stalled progress. The loss of potential revenue to neighboring states (NY, NJ, OH, MD) is a pressure point, but political gridlock persists.

  • Virginia: The legislative commission has recommended a November 2026 start date for adult-use sales. This is later than many investors hoped, extending the "burn" period for Jushi's VA assets before they can reach full utilization.

Litigation & Market Threats

• Antitrust Lawsuit (MJ's Market Inc. v. Jushi): Jushi is defending against a class-action antitrust lawsuit in Massachusetts alleging conspiracy to block competitors. While many such cases settle, an adverse judgment could result in significant treble damages.

• Hemp-Derived Competitors: The proliferation of unregulated "intoxicating hemp" (Delta-8/9) products sold in gas stations and smoke shops undermines the regulated market. Jushi has proactively filed lawsuits against hemp distributors in Pennsylvania to protect its market share. If courts do not uphold the distinction between regulated cannabis and hemp-derived intoxicants, Jushi’s "limited license" moat could be eroded by unregulated competitors with zero compliance costs.

5. 5-Year Scenario Analysis

This analysis projects shareholder returns through 2030. The calculations rely on the assumption of a fully diluted share count of roughly 300 million shares (accounting for warrant/option exercises). The current share price reference is $0.60 USD.

Scenario A: High Case ("The Regulatory Supercycle")

Narrative:

• Federal: Cannabis is rescheduled to Schedule III by Q2 2026. Section 280E is eliminated retroactively for 2026.

• State: Pennsylvania passes adult-use legislation in mid-2026 with sales starting Jan 1, 2027. Virginia accelerates sales to mid-2026.

• Financials: The elimination of 280E saves Jushi ~$15M+ annually in cash taxes. This newfound cash flow allows for non-dilutive refinancing of the 2026 notes at blended rates <10%.

• Operational: Jushi captures 10% market share in PA and VA adult-use markets.

Financial Model Inputs (2030 Projections):

• Revenue: Grows at 18% CAGR to $600 Million. (Driven by PA becoming a $2B market and VA a $1B market).

• EBITDA Margin: Expands to 28% due to scale and removal of 280E distortions.

• 2030 EBITDA: $168 Million.

• Target Multiple: 10.0x EV/EBITDA (Reflecting a normalized CPG-like environment and M&A premium).

Valuation Output:

• Enterprise Value: $1.68 Billion ($168M x 10).

• Net Debt: $150 Million (Reduced significantly via free cash flow).

• Equity Value: $1.53 Billion.

• Share Count: 300 Million.

• Projected Share Price: $5.10 USD.

• Return: ~750%.

Scenario B: Base Case ("Muddle Through")

Narrative:

• Federal: Rescheduling happens late 2026/early 2027. 280E relief is delayed.

• State: PA passes adult-use but implementation drags to 2028. VA launches in Nov 2026 as planned.

• Financials: Jushi refinances the 2026 notes but at high costs (12%+), requiring some warrant coverage (dilution). Growth is steady but capital-constrained.

Financial Model Inputs (2030 Projections):

• Revenue: Grows at 10% CAGR to $420 Million.

• EBITDA Margin: Stabilizes at 22% (Operational efficiencies offset by continued tax burden for 1-2 years).

• 2030 EBITDA: $92 Million.

• Target Multiple: 7.5x EV/EBITDA (Standard Tier 2 multiple).

Valuation Output:

• Enterprise Value: $690 Million ($92M x 7.5).

• Net Debt: $200 Million (Debt principal remains high due to slower repayment).

• Equity Value: $490 Million.

• Share Count: 320 Million (Slight dilution from refinancing).

• Projected Share Price: $1.53 USD.

• Return: ~155%.

Scenario C: Low Case ("The Debt Trap")

Narrative:

• Federal: Rescheduling is blocked by litigation. 280E remains indefinitely.

• State: PA fails to legalize due to political gridlock. VA implementation is botched or delayed.

• Financials: Jushi hits the Dec 2026 debt wall without sufficient cash. Forced into a distressed exchange or highly dilutive equity raise to pay off noteholders.

Financial Model Inputs (2030 Projections):

• Revenue: Stagnates at $290 Million (Growth only from inflation/minor optimization).

• EBITDA Margin: Compresses to 15% due to price wars and lack of scale.

• 2030 EBITDA: $43.5 Million.

• Target Multiple: 5.0x EV/EBITDA (Distressed valuation).

Valuation Output:

• Enterprise Value: $217.5 Million.

• Net Debt: $220 Million.

• Equity Value: $0 (Technically insolvent or essentially wiped out).

• Projected Share Price: $0.05 USD (Option value only).

• Return: -92%.

Probability Weighted Target

Summary: ASYMMETRIC UPSIDE WITH EXISTENTIAL RISK

6. Qualitative Scorecard

Overall Blended Score: 5.8/10 Summary: HIGH RISK, HIGH ALIGNMENT TURNAROUND

7. Conclusion & Investment Thesis

Jushi Holdings represents a classic capital structure arbitrage play within the U.S. cannabis sector. The equity is currently priced as a distressed option, reflecting legitimate fears regarding the December 2026 debt maturities and the uncertain timeline of federal and state reforms.

However, the operational turnaround is evident. With gross margins recovering to nearly 47% and positive operating cash flow, the core business is functioning well. The investment thesis rests on a "Triple Catalyst" convergence in 2026:

1. Federal Rescheduling (Schedule III): This is the "magic bullet." Elimination of Section 280E would instantly improve Jushi's cash flow by ~$15M annually , drastically altering its credit profile and allowing for a successful debt refinance.

2. Pennsylvania Legalization: As the holder of ~18 dispensaries in a potential $2.1 billion adult-use market, Jushi is arguably the most levered public equity play on PA legalization.

3. Virginia Activation: The start of adult-use sales in Nov 2026 would unlock the value of Jushi's Northern Virginia monopoly.

Catalysts:

• Q1/Q2 2026: Final DEA Rule on Rescheduling.

• Mid-2026: PA State Budget passage (potential inclusion of adult-use).

• Nov 2026: Launch of VA adult-use sales.

Risks:

• The Debt Wall: Failure to refinance the Dec 2026 notes would likely result in massive equity dilution or restructuring.

• Regulatory Delay: If 280E remains and PA/VA stall, the cash burn becomes unsustainable.

Summary: LEVERAGED REGULATORY CALL OPTION

8. Technical Analysis, Price Action & Short-Term Outlook

As of January 3, 2026, Jushi stock (JUSH.CN) trades at approximately $0.85 CAD ($0.63 USD). The stock is currently trading below its 200-day moving average, confirming a long-term bearish trend consistent with the broader cannabis sector. While the 50-day moving average has acted as resistance, the Relative Strength Index (RSI) is hovering near 48-51, indicating neutral momentum with no immediate overbought/oversold signal. Recent price action shows consolidation in the $0.60 USD range. Short-term outlook remains cautious; the stock needs a definitive regulatory headline to break the current downtrend and reclaim the 200-day moving average.

Summary: OVERSOLD CONSOLIDATION IN DOWNTREND